The Global Flow Cytometry Market, by Technology (Cell based & Bead based), by Product Type (Analyzer, Sorter, & Reagent & Consumables), by Application (Research, Clinical and Industrial), by End User (Hospital, Clinical Testing Laboratories and Research laboratories), and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 3.02 Bn in 2016 and is projected to exhibit a CAGR of 10.2% over the forecast period (2017–2025). Increasing demand in disease diagnosis and advancement in technology of flow cytometry, in turn is projected to fuel growth of the flow cytometry market over the forecast period. Manufacturers are focusing on innovation to tap into emerging markets. For instance, in August 2017, Beckman Coulter Life Sciences received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its latest clinical flow cytometry product, the Navios EX flow cytometer, to be used in the clinical laboratory in the U.S. Furthermore, Sysmex America, Inc. announced in October 2017, introduction of CyFlow Antibodies a comprehensive portfolio of Analyte Specific Reagent (ASR) antibodies for use in flow cytometry applications, as a part of its initiative to offer cutting-edge clinical laboratory products. In March 2017, Cytek Biosciences Inc., a manufacturer and supplier of flow cytometry products and services, launched its DxP Athena flow cytometry system. The system is compact, powerful, easy-to-use cell analyzer that are typically only found in instruments that come with a much higher price tag. The DxP Athena makes the benefits of flow cytometry more readily available to a larger number of researchers through its compact size.
Browse 30 Market Data Tables and 28 Figures spread through 140 Pages and in-depth TOC on Flow Cytometry Market, by Technology (Cell based & Bead based), by Product Type (Analyzer, Sorter, Reagent & Consumables), by Application (Research, Clinical and Industrial), by End User (Hospital, Clinical Testing Laboratories and Research laboratories), and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Global Forecast to 2025.
To know the latest trends and insights prevalent in the flow cytometry market, click the link below:
Beckman Coulter received FDA clearance for first IVD test ClearLLab, in July 2017, delivering flow cytometric leukemia & lymphoma analysis, where the FDA confirmed that the test provides consistent results to aid in the diagnoses of leukemia & lymphoma cancers. These ClearLLab reagents delivered the first preformulated, IVD antibody cocktails for leukemia and lymphoma immunophenotyping in July 2017. ClearLLab Reagents consist of five pre-formulated antibody cocktails targeted at B-, T-, and Myeloid cell malignancies, which reduce validation time significantly, owing to their in vitro diagnostic status. Furthermore, flow cytometry continues to evolve at a fast pace and provide scientists with the ability to perform many highly-specialized assays simultaneously, which supports an increasing use of flow cytometry in research laboratories.
Key takeaways of the market:
Some major players operating in the global flow cytometry market are Becton Dickinson and Company, General Electric Company, Luminex Corporation, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Miltenyi Biotec GmbH, Merck & Co Inc., Sysmex Corporation, Agilent Technologies, Inc. and Danaher Corporation.
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.